Skip to main content

Advertisement

SpringerLink
Log in

Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

We previously reported in the SENRI trial on the usefulness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in colorectal cancer patients receiving an oxaliplatin-based regimen which is classified as moderately emetogenic cancer chemotherapy. In the present subgroup analysis of the SENRI trial, we assessed the risk factors for CINV in colorectal cancer patients who received oxaliplatin-based chemotherapy.

Methods

Multivariate logistic regression models were used to assess the impact of aprepitant use and patient characteristics on vomiting and nausea. We also assessed the proportion of CINV in patients by gender.

Results

Female gender and aprepitant use were associated with the incidence of vomiting and no significant nausea. Significantly more men achieved no vomiting than women (92.9 vs 84.5 % in men and women, respectively; P = 0.0001). The rate of no nausea, complete response, complete protection, and total control was also higher in men. The rate rescue therapy use was significantly higher in women than men. We compared the rate of CINV between aprepitant and control groups and found a significant difference in male patients who achieved no vomiting and complete protection in the overall phase. In women, the rate of no nausea, no vomiting, and total control was higher in the aprepitant group than in the control group.

Conclusions

Gender and aprepitant use were risk factors for CINV in colorectal patients who received oxaliplatin-based chemotherapy. Aprepitant therapy was more effective for women than for men in the prevention of CINV in colorectal cancer patients receiving an oxaliplatin-based regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Network NCCN (2016) NCCN clinical practice guidelines in oncology: antiemesis

  2. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243

    Article  PubMed  Google Scholar 

  3. Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198

    Article  PubMed  PubMed Central  Google Scholar 

  4. Oncology JSoC (2010) Guideline: appropriate use of antiemetics. Kanehara & Co., Ltd, Tokyo (in Japanese)

    Google Scholar 

  5. Nishimura J, Satoh T, Fukunaga M et al (2015) Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 51:1274–1282

    Article  CAS  PubMed  Google Scholar 

  6. Hesketh PJ, Aapro M, Street JC et al (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18:1171–1177

    Article  PubMed  Google Scholar 

  7. Hesketh PJ, Grunberg SM, Herrstedt J et al (2006) Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14:354–360

    Article  CAS  PubMed  Google Scholar 

  8. Poon KS, Un MK, Low XH et al (2013) Impact of cancer-related fatigue on chemotherapy-induced nausea and vomiting in Asian cancer patients. Pharmacoepidemiol Drug Saf 22:1345–1351

    Article  CAS  PubMed  Google Scholar 

  9. Roila F, Tonato M, Basurto C et al (1989) Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol 7:1693–1700

    CAS  PubMed  Google Scholar 

  10. Sekine I, Segawa Y, Kubota K et al (2013) Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci 104:711–717

    Article  CAS  PubMed  Google Scholar 

  11. Tamura K, Aiba K, Saeki T et al (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20:855–865

    Article  PubMed  Google Scholar 

  12. Tonato M, Roila F, Del Favero A (1991) Methodology of antiemetic trials: a review. Ann Oncol 2:107–114

    Article  CAS  PubMed  Google Scholar 

  13. Rapoport BL (2014) Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region. Curr Med Res Opin 30:1875–1881

    Article  CAS  PubMed  Google Scholar 

  14. Celio L, Denaro A, Agustoni F et al (2012) Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. J Support Oncol 10:65–71

    Article  CAS  PubMed  Google Scholar 

  15. Hesketh PJ, Younger J, Sanz-Altamira P et al (2009) Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer 17:1065–1070

    Article  PubMed  Google Scholar 

  16. Hickok JT, Roscoe JA, Morrow GR et al (2005) 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 6:765–772

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Sullivan JR, Leyden MJ, Bell R (1983) Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med 309:796

    CAS  PubMed  Google Scholar 

  18. Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830

    Article  CAS  PubMed  Google Scholar 

  19. Oechsle K, Muller MR, Hartmann JT et al (2006) Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone. Onkologie 29:557–561

    CAS  PubMed  Google Scholar 

  20. Wu CE, Liaw CC (2012) Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis. Support Care Cancer 20:2357–2361

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study is supported by a grant from The Supporting Center for Clinical Research and Education (Osaka, Japan), a nonprofit foundation. We thank the patients for their participation in this study, the study management team and staff at individual study sites. Participating institusions included Hannan Chuo Hospital, Higashiosaka City General Hospital, Hyogo Prefectural Nishinomiya Hospital, Ikeda Municipal Hospital, Iseikai Hospital, Japan Community Health care Organization Osaka Hospital, Japan Community Health care Organization Osaka Minato Central Hospital, Kaizuka City Hospital, Kansai Rosai Hospital, Kawasaki hospital, Kindai University Nara Hospital, Kinki Central Hospital, Minoh City Hospital, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, National Hospital Organization Osaka National Hospital, Nippon Telegraph and Telephone West Corporation Osaka Hospital, Nishinomiya Municipal Hospital, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka University Hospital, Rinku General Medical Center, Saiseikai Senri Hospital, Sakai city hospital, Suita Municipal Hospital, Toyonaka Municipal Hospital, Yao Municipal Hospital.

Author information

Authors and Affiliations

  1. Department of Surgery, Kinki Central Hospital, Kurumaduka 3-1, Itami, Hyogo, Japan

    Hiroyoshi Takemoto

  2. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, Japan

    Junichi Nishimura, Taishi Hata, Ichiro Takemasa, Tsunekazu Mizushima, Yuichirou Doki & Masaki Mori

  3. Department of Surgery, Toyonaka Municipal Hospital, Shibahara 4-14-1, Toyonaka, Osaka, Japan

    Takamichi Komori

  4. Department of Surgery, Rinku General Medical Center, Rinku Ourai Kita 2-23, Izumisano, Osaka, Japan

    Ho Min Kim

  5. Department of Digestive Surgery, Ikeda City Hospital, Jyounan 3-1-18, Ikeda, Osaka, Japan

    Hirofumi Ota

  6. Department of Surgery, Itami City Hospital, Koyaike 1-100, Itami, Hyogo, Japan

    Rei Suzuki

  7. Department of Surgery, Higashiosaka City General Hospital, Nishiiwata 3-4-5, Higashiosaka, Osaka, Japan

    Masakazu Ikenaga

  8. Department of Surgery, National Hospital Organization, Osaka National Hospital, Hoenzaka 2-1-14, Osaka, Osaka, Japan

    Masataka Ikeda

  9. Division of Health Sciences, Graduate School of Medicine, Department of Molecular Pathology, Osaka University, Yamadaoka 1-7, Suita, Osaka, Japan

    Hirofumi Yamamoto

  10. Department of Frontier-Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita, Osaka, Japan

    Taroh Satoh

Authors
  1. Hiroyoshi Takemoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Junichi Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takamichi Komori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ho Min Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hirofumi Ota
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rei Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masakazu Ikenaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masataka Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hirofumi Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Taroh Satoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Taishi Hata
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ichiro Takemasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tsunekazu Mizushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yuichirou Doki
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Masaki Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO)

Corresponding author

Correspondence to Junichi Nishimura.

Ethics declarations

Conflict of interest

TS has received consulting fees from Eli Lilly, Daiici Sankyo, Ono Pharmaceutical, Merck Serono Co. Ltd, Bayer Pharmaceutical Co. Ltd, and Chugai Pharmaceutical Co. Ltd; honoraria from Chugai Pharmaceutical Co. Ltd, Merck Serono Co. Ltd, Bristol-Myers K.K., Taiho Pharmaceutical Co. Ltd, Bayer Pharmaceutical Co.Ltd and Takeda Pharmaceutical Co. Ltd; and departmental research grants from Chugai Pharmaceutical Co. Ltd and Yakult Honsha Co. Ltd. All other authors have declared no conflict of interest.

Additional information

Hiroyoshi Takemoto and Junichi Nishimura are joint first authors.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takemoto, H., Nishimura, J., Komori, T. et al. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. Int J Clin Oncol 22, 88–95 (2017). https://doi.org/10.1007/s10147-016-1022-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-016-1022-9

Keywords

Search

Navigation